LAVA Therapeutics N.V. (LVTX)

Market Cap	45.77M -4.4%
Revenue (ttm)	4.99M -32.1%
Net Income	-23.18M
EPS	-0.86
Shares Out	26.31M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	285,521
Open	1.810
Previous Close	n/a
Day's Range	1.620 - 1.820
52-Week Range	0.850 - 2.000
Beta	0.50
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 6, 2025

About LVTX

LAVA Therapeutics N.V. operates as a clinical-stage immuno-oncology company that focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabo...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 25, 2021
• Employees: 34
• Stock Exchange: NASDAQ
• Ticker Symbol: LVTX
• Website: https://www.lavatherapeutics.com

Financial Performance

In 2024, LAVA Therapeutics's revenue was $11.98 million, an increase of 77.01% compared to the previous year's $6.77 million. Losses were -$25.11 million, -40.02% less than in 2023.

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Jan 1, 2000

Data Sources Report a data error